<DOC>
	<DOC>NCT00484185</DOC>
	<brief_summary>To provide safety and effectiveness information of BeneFIX during the post-marketing period as required by Korea FDA regulations, to identify any potential drug related treatment factors in Korean population including: 1) Unknown adverse reactions, especially serious adverse reactions; 2) Changes in the incidences of adverse reactions under the routine drug uses. 3) Factors that may affect the safety of the drug 4) Factors that may affect the effectiveness of the drug</brief_summary>
	<brief_title>Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B</brief_title>
	<detailed_description>The patients who meet the inclusion criteria will be enrolled consecutively.</detailed_description>
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Hemophilia B</mesh_term>
	<criteria>Patients or legally authorized representatives of pediatric patients agree to provide written informed consent form (data privacy statement). Pediatric and adult patients who have been treated with original or reformulated BeneFIX for hemophilia B (congenital factor IX deficiency or Christmas disease) from first approved date by KFDA, or who are planned to be newly prescribed BeneFIX (for example, patients switching from pdFIX to BeneFIX). Patients with a known history of hypersensitivity to original or reformulated BeneFIX or any component of the product. Patients with a known history of hypersensitivity to hamster protein. Patients participating in an interventional trial of any investigational drug or device.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Hemophilia B</keyword>
	<keyword>BeneFIX</keyword>
	<keyword>Safety</keyword>
	<keyword>Efficacy</keyword>
</DOC>